59 completed, 44 unknown, 22 recruiting, 17 not yet recruiting. 118 Phase 2, 28 Phase 1, 27 Phase 3, 4 Phase 4, 3 Not applicable.
Follow S-1: new trials by email Literature Review of S-1 trials Research Report on S-1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard Therapy Becotatug Vedotin, Anti-PD-1 antibody, S-1 - Pancreatic Cancer | Not applicable | Recruiting | Ningbo Medical Center Lihuili Hospital | 27 | 2026-10-07 | 2026-10-23 |
| Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial Retlirafusp alfa, Famitinib malate, Gemcitabine & oxaliplatin - Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 81 | 2026-09-30 | 2026-10-23 |
| Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Serplulimab and Bevacizumab injection, FOLFIRINOX/NALIRIFOX, S-1 - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | Shanghai General Hospital, China | 34 | 2026-08-01 | 2026-07-29 |
| Neoadjuvant Propranolol Plus SOX and Toripalimab for Locally Advanced Gastric/GEJ Adenocarcinoma propranolol, Toripalimab, Oxaliplatin - Gastric or Gastroesophageal Junction Adenocarcinoma, Propranolol | Phase 1 / Phase 2 | Not yet recruiting | Ting Liu | 49 | 2026-08-01 | 2026-07-27 |
| Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer Multimodal Thermal Therapy (MTT) System, KRAS G12V mRNA Vaccine, Sintilimab - Pancreatic Ductal Adenocarcinoma, Liver Neoplasms | Phase 2 | Not yet recruiting | Ruijin Hospital | 20 | 2026-07-13 | 2026-08-04 |
| HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer Hyperthermic Intraperitoneal Chemotherapy, Serplulimab, S-1 - Locally Advanced Gastric Cancer, Gastric Adenocarcinoma | Phase 2 | Recruiting | Shanghai Changzheng Hospital | 48 | 2026-07-13 | 2026-10-22 |
| Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study Zanidatamab, Oxaliplatin, Capecitabine - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Zhifeng Zhao, PhD | 46 | 2026-07-01 | 2026-07-06 |
| Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction Iparomlimab and Tuvonralimab Injection (QL1706), S-1, Oxaliplatin - Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | Phase 2 | Active not recruiting | Yongxu Jia | 34 | 2026-05-10 | 2026-09-09 |
| SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis SHR-1701, Capecitabine, S-1 - Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | Ruijin Hospital | 60 | 2026-04-24 | 2026-07-23 |
| Adebrelimab Plus S-1 for Resected Cholangiocarcinoma Adebrelimab, S-1 - Cholangiocarcinoma, Biliary Tract Cancer | Phase 2 | Not yet recruiting | Xingjun Guo | 40 | 2026-04-21 | 2026-05-01 |
| Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma Sintilimab, Bevacizumab, Oxaliplatin - Gastric Cancer (GC), AFP Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Fudan University | 46 | 2026-04-01 | 2026-04-07 |
| Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma Ivonescimab (20mg/kg Q3W), Oxaliplatin, S-1 - Gastric Cancer, RCT | Phase 2 | Not yet recruiting | Sichuan University | 154 | 2026-02-01 | 2026-01-28 |
| Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) short-course radiotherapy, Zanidatamab, Tisleizumab(BGB-A317) - Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Tao Zhang | 70 | 2026-01-15 | 2025-11-24 |
| Maintenance Therapy in Metastatic Gastric Cancer: A Multicenter Retrospective Study in Colombia Fluoropyrimidine Maintenance Therapy, Immune Checkpoint Inhibitor Maintenance, Targeted Therapy Maintenance - Stomach Neoplasms, Gastric Adenocarcinoma | Recruiting | Fundación Santa Fe de Bogota | 150 | 2026-01-01 | 2026-10-02 | |
| Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer nab-paclitaxel, oxaliplatin, S-1 - Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma | Phase 2 | Not yet recruiting | zhoujing | 35 | 2025-10-01 | 2025-06-12 |
| Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer Disitamab vedotin(RC48), Sintilimab, S-1 - Gastric Cancer | Phase 2 | Recruiting | Fudan University | 30 | 2025-09-04 | 2025-09-26 |
| Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis S-1 - Pancreatic Cancer, Postoperative Adjuvant Therapy | Phase 4 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 464 | 2025-07-01 | 2025-04-03 |
| Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma Tislelizumab - Cholangiocarcinoma, Biliary Tract Cancer (BTC) | Phase 2 | Not yet recruiting | National Cheng-Kung University Hospital | 35 | 2025-07-01 | 2025-03-30 |
| Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial Ivonescimab, Nimotuzumab, Irinotecan liposome - Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | Recruiting | Ming-Yuan Chen | 208 | 2025-06-24 | 2025-09-18 |
| IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer IBI343, Sintilimab, Oxaliplatin - Gastric Cancer | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 55 | 2025-06-02 | 2026-08-18 |
Showing 20 of 166. Sign in to see all of them.
Stomach Neoplasms (70) · Pancreatic Neoplasms (21) · Esophageal Neoplasms (11) · Biliary Tract Neoplasms (7) · Cholangiocarcinoma (6) · Esophageal Squamous Cell Carcinoma (6) · Colorectal Neoplasms (5) · Nasopharyngeal Carcinoma (5) · Carcinoma, Non-Small-Cell Lung (4) · Gastrointestinal Neoplasms (3) · Head and Neck Neoplasms (3) · Neoplasm Metastasis (3) · Neoplasms (3) · Rectal Neoplasms (3) · Recurrence (3)
Fudan University (10) · Chinese Academy of Medical Sciences (9) · The First Affiliated Hospital with Nanjing Medical University (9) · Sun Yat-sen University (8) · Taiho Oncology, Inc. (8) · Hokkaido Gastrointestinal Cancer Study Group (6) · National Health Research Institutes, Taiwan (5) · Fujian Cancer Hospital (4) · Zhejiang Cancer Hospital (4) · Chinese PLA General Hospital (3) · Japan Clinical Cancer Research Organization (3) · Ono Pharmaceutical Co., Ltd. (3) · Ruijin Hospital (3) · Sanofi (3) · Tianjin Medical University Cancer Institute and Hospital (3)
China (92) · Japan (27) · South Korea (16) · Taiwan (11) · United States (7) · France (5) · Italy (4) · Brazil (3) · Germany (3) · Spain (3) · Australia (2) · Guatemala (2) · Israel (2) · New Zealand (2) · Poland (2)
Fabio Benedetti, MD (3) · Masahiro Asaka, MD, PhD (3) · Project Leader (3) · Hiroaki Nagano, MD, PhD (2) · Rongbo Lin, MD (2) · Sang-Hee Cho, M.D.Ph.D. (2) · Taiho Central (2) · Yoshito Komatsu, MD, PhD (2) · Aiguang Zhao, M.D.,Ph.D (1) · Aiping Zhou, M.D (1) · Andrew Ko, MD (1) · Binghe Xu, M.D. (1)
PMID 34351356, PMID 35219300, PMID 37195667, PMID 10581077, PMID 11556297, PMID 15928658, PMID 18553228, PMID 21365500, PMID 21444866, PMID 22189752, PMID 23497365, PMID 23547081, PMID 23664139, PMID 23665950, PMID 24366758, PMID 24514954, PMID 24618998, PMID 24662266, PMID 24737677, PMID 24889903, PMID 25273077, PMID 25612635, PMID 25943068, PMID 26385385, PMID 26412280, PMID 26808342, PMID 27076940, PMID 27156933, PMID 27913881, PMID 28102259, PMID 28457713, PMID 28536493, PMID 28622514, PMID 29119276, PMID 29190925, PMID 29342492, PMID 29370182, PMID 29961579, PMID 30373600, PMID 30479382, PMID 30566590, PMID 30911859, PMID 30940189, PMID 31036088, PMID 31221115, PMID 31373648, PMID 31513484, PMID 31765987, PMID 32246224, PMID 32437711
2014 (1), 2016 (1), 2018 (1), 2023 (1)